Advertisement
Advertisement
AYTU
AYTU BioPharma, Inc. Common Stock
2.40
USDSponsored
+0.02
+0.86%
Aug 11, 15:59 UTC -4
Closed
After-Market
2.41
+0.01
+0.40%
AYTU Earnings Reports
Positive Surprise Ratio
AYTU beat 21 of 38 last estimates.
55%
Next Report
Date of Next Report
Sep 21, 2026
Estimate for Q4 26 (Revenue/ EPS)
$12.52M
/-$0.33
Implied change from Q3 26 (Revenue/ EPS)
+0.89%
/-37.74%
Implied change from Q4 25 (Revenue/ EPS)
-17.27%
/-88.70%
AYTU BioPharma, Inc. Common Stock earnings per share and revenue
On May 13, 2026, AYTU reported earnings of -0.53 USD per share (EPS) for Q3 26, missing the estimate of -0.52 USD, resulting in a -1.88% surprise. Revenue reached 12.41 million, compared to an expected 12.29 million, with a 0.95% difference. The market reacted with a +0.89% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 5 analysts forecast an EPS of -0.33 USD, with revenue projected to reach 12.52 million USD, implying an decrease of -37.74% EPS, and increase of 0.89% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Imunon, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.94
Actual
-$0.54
Surprise
+42.83%
Dermata Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.56
Actual
-$0.74
Surprise
-31.91%
Apogee Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$1.09
Actual
-$1.13
Surprise
-4.39%
Legend Biotech Corporation - ADR
Report Date
Aug 11, 2026 For Q2 26
Estimate
$0.07
Actual
$0.09
Surprise
+17.80%
Mineralys Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.54
Actual
-$2.85
Surprise
-422.26%
Bicara Therapeutics Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.84
Actual
-$0.82
Surprise
+3.18%
Autolus Therapeutics plc - ADR
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.22
Actual
-$0.15
Surprise
+31.82%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
$0.01
Actual
$0.05
Surprise
+400.00%
LENZ Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$1.09
Actual
-$1.02
Surprise
+6.95%
Codexis, Inc.
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.13
Surprise
+7.67%
FAQ
What were AYTU BioPharma, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, AYTU BioPharma, Inc. Common Stock reported EPS of -$0.53, missing estimates by -1.88%, and revenue of $12.41M, 0.95% above expectations.
How did the market react to AYTU BioPharma, Inc. Common Stock's Q3 2026 earnings?
The stock price moved up 0.89%, changed from $2.25 before the earnings release to $2.27 the day after.
When is AYTU BioPharma, Inc. Common Stock expected to report next?
The next earning report is scheduled for Sep 21, 2026.
What are the forecasts for AYTU BioPharma, Inc. Common Stock's next earnings report?
Based on 5
analysts, AYTU BioPharma, Inc. Common Stock is expected to report EPS of -$0.33 and revenue of $12.52M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement